Abstract
Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29-yr-old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic reaction during the second dose of brentuximab vedotin. A 12-step desensitization protocol was followed; after premedicating with antihistaminic agents, methylprednisolone and montelukast, a total dose of 156mg of brentuximab vedotin (1.8mg/kg) was given as three infusions with increasing rate and concentration. Such desensitization protocol can allow safe administration of brentuximab vedotin and may have a broader applicability in managing hypersensitivity reactions with other monoclonal antibodies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 361-364 |
| Number of pages | 4 |
| Journal | European Journal of Haematology |
| Volume | 95 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 1 2015 |
Keywords
- Anaphylaxis
- Brentuximab vedotin
- Desensitization
- Hodgkin's lymphoma
ASJC Scopus subject areas
- Hematology